
Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial
In the pivotal phase 3 REGAL trial, galinpepimut-S was generally well tolerated among patients with acute myeloid leukemia.
The investigational WT1-targeting immunotherapeutic cancer vaccine galinpepimut-S (GPS) produced a statistically significant and clinically meaningful improvement in overall survival (OS) as maintenance therapy compared with investigator’s choice of best available treatment (BAT) in patients with acute myeloid leukemia (AML) in a second or later remission who were ineligible for transplantation, meeting the primary end point of the pivotal phase 3 REGAL trial (NCT04229979), according to topline results announced by the developer, SELLAS Life Sciences.¹
What were the survival outcomes?
In the REGAL trial, the median OS was 24.0 months among patients treated with galinpepimut-S vs 14.7 months with BAT, corresponding to a 41% reduction in the risk of death (HR, 0.59; two-sided P = .035). The topline primary end point analysis was conducted following the prespecified occurrence of 80 deaths, in accordance with the trial’s statistical analysis plan. According to SELLAS, both treatment arms were well balanced for prognostic stratification factors, and the small number of patients who proceeded to hematopoietic stem cell transplantation were equally distributed between the arms.
What was the safety profile?
Galinpepimut-S was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate (grade 1 or 2) and mostly consisted of local injection site reactions.
“REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in [OS] for patients with AML who have very limited options after achieving a second remission,” said Angelos Stergiou, MD, ScD h.c., president and chief executive officer of SELLAS, in a news release.1 “The magnitude of the survival benefit observed with our investigational GPS immunotherapeutic cancer vaccine represents a defining milestone for SELLAS and provides phase 3 validation of our WT1-targeted immunotherapeutic technology.”
The REGAL Study Steering Committee was chaired by global principal investigator Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, with Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center, and M. Yair Levy, MD, of Texas Oncology-Baylor Charles A. Sammons Cancer Center. They added that patients in this setting experience “poor survival outcomes and have a significant need for new treatment approaches,” and that “by training the immune system to target residual leukemia cells, GPS addresses a critical unmet need and has the potential to redefine the treatment paradigm in AML maintenance therapy.”1
What was the REGAL trial design?
REGAL is a global, randomized, open-label, registrational phase 3 trial that enrolled 126 patients with AML who had achieved a second complete remission or later (CR2 or later) or CR with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.2 Patients were randomly assigned 1:1 to galinpepimut-S monotherapy or investigator’s choice of BAT, which comprised observation, a hypomethylating agent, venetoclax (Venclexta), and/or low-dose cytarabine.
The primary end point was OS from the time of study entry. Secondary end points included safety and tolerability, leukemia-free survival, antigen-specific T-cell immune response dynamics, and measurable residual disease.
Galinpepimut-S is an off-the-shelf immunotherapeutic cancer vaccine, licensed from Memorial Sloan Kettering Cancer Center, that consists of 4 WT1-derived peptides designed to stimulate CD4-positive and CD8-positive T-cell responses against WT1-expressing cancer cells across multiple HLA types.
What are the next steps?
Developers plan to meet with the FDA to discuss an accelerated filing strategy and to advance preparations for a biologics license application submission for galinpepimut-S in the first half of 2027. A comprehensive analysis of all secondary end points and additional prespecified analyses is underway and is expected to be presented at an upcoming medical meeting and submitted for publication in a peer-reviewed journal.
References
- SELLAS Life Sciences announces positive pivotal phase 3 REGAL trial data showing immunotherapeutic cancer vaccine, galinpepimut-S (GPS), demonstrated a statistically significant and clinically meaningful improvement in overall survival in patients with acute myeloid leukemia. News release. SELLAS Life Sciences Group, Inc. November 17, 2026. Accessed November 18, 2026. https://tinyurl.com/mu5kjzhr
- Galinpepimut-S versus investigator’s choice of best available therapy for maintenance in AML CR2/CRp2 (REGAL). ClinicalTrials.gov. Updated October 1, 2025. Accessed November 18, 2026. https://tinyurl.com/y93dd9wj
Related to this article








